Foghorn Therapeutics Inc
$ 5.67
-1.39%
24 Feb - close price
- Market Cap 336,844,000 USD
- Current Price $ 5.67
- High / Low $ 5.90 / 5.64
- Stock P/E N/A
- Book Value -1.59
- EPS -1.14
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -4.70 %
- 52 Week High 6.95
- 52 Week Low 2.94
About
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$11.44
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-05 | 2025-05-05 | 2025-03-05 | 2024-10-31 | 2024-08-08 | 2024-05-06 | 2024-03-07 | 2023-11-02 | 2023-08-04 | 2023-05-08 | 2023-03-09 |
| Reported EPS | -0.25 | -0.28 | -0.3 | -0.3 | -0.31 | -0.45 | -0.59 | -0.57 | -0.34 | -0.7 | -0.73 | -0.69 |
| Estimated EPS | -0.3333 | -0.3514 | -0.29 | -0.285 | -0.44 | -0.65 | -0.63 | -0.76 | -0.75 | -0.73 | -0.72 | -0.62 |
| Surprise | 0.0833 | 0.0714 | -0.01 | -0.015 | 0.13 | 0.2 | 0.04 | 0.19 | 0.41 | 0.03 | -0.01 | -0.07 |
| Surprise Percentage | 24.9925% | 20.3187% | -3.4483% | -5.2632% | 29.5455% | 30.7692% | 6.3492% | 25% | 54.6667% | 4.1096% | -1.3889% | -11.2903% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FHTX
2026-02-24 14:52:21
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and The Citizens Life Sciences Conference on March 11, 2026. President and CEO Adrian Gottschalk will present at both events. The company, a clinical-stage biotechnology firm, specializes in correcting abnormal gene expression through its Gene Traffic Control® platform, with an initial focus on oncology.
2026-02-24 11:52:21
Foghorn Therapeutics Inc. announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference and The Citizens Life Sciences Conference. Adrian Gottschalk, President and CEO, will present at both events in early March 2026 and engage in one-on-one meetings, discussing the company's clinical-stage biotechnology and Gene Traffic Control® platform. Webcasts of the presentations will be available on the company's website.
2026-02-23 22:03:20
Foghorn Therapeutics Inc. has appointed Ryan Maynard as its new Chief Financial Officer. Maynard brings 25 years of experience in biopharmaceutical and healthcare technology, having raised over $1 billion in his career. The company maintains a strong financial position with more cash than debt and an InvestingPro analysis suggesting its stock is undervalued, with optimistic analyst price targets.
2026-02-23 12:36:35
Foghorn Therapeutics has appointed Ryan D. Maynard as its new Chief Financial Officer, succeeding interim CFO Jeff Sacher. Maynard brings over 25 years of experience in financial strategy and capital markets in the biopharmaceutical sector, having previously served as CFO for several other companies. His expertise is expected to bolster Foghorn's financial leadership as the company advances its oncology pipeline and partnership programs.
2026-02-23 12:10:35
Foghorn Therapeutics Inc. has appointed Ryan Maynard as its new Chief Financial Officer, effective February 23, 2026. Maynard brings over 25 years of experience in financial strategy, capital markets, and operational leadership within the biopharmaceutical sector, having previously served as CFO at Cara Therapeutics. His appointment is expected to strengthen Foghorn's financial leadership as the company advances its drug development pipeline, including its lead program in partnership with Lilly.
2026-02-23 11:59:35
Foghorn Therapeutics has appointed Ryan Maynard as its new Chief Financial Officer, effective February 23, 2026. Maynard brings over 25 years of biopharmaceutical financial leadership, including raising more than $1 billion in capital and leading significant strategic transactions. His appointment is expected to strengthen Foghorn's financial strategy as the company advances its pipeline and prepares for commercialization.
